Results 91 to 100 of about 248,684 (153)

From Limits to Growth to Unlimited Wellbeing: A Revolutionary’s Vision of Wealth and Welfare

Cadmus, 2020
Garry Jacobs, Ivo Šlaus
doaj  

Real-World Impact of Insurance Changes on Long-acting Cabotegravir Plus Rilpivirine Delivery. [PDF]

Open Forum Infect Dis
Davis JM, O'Neill J, Lyden E, Bares SH.
europepmc   +1 more source

Virologic, immunologic, and metabolic outcomes and mortality in people with HIV on bictegravir/emtricitabine/tenofovir alafenamide fumarate versus dolutegravir-based antiretroviral therapies: a retrospective multicenter cohort study in China. [PDF]

Lancet Reg Health West Pac
Wu X, Ma P, Ruan L, Chen Y, Wang R, Song Y, Cai Y, Chen F, Zhang L, Fitzpatrick T, Li B, Wu G, Meng X, Fan S, Qiao Y, Gao Y, Hong Z, Zhang T, Zou M, Wang L, Fu Y, Su B, Zou J, Wang H, Zou H.   +24 more
europepmc   +1 more source

Recovery through creativity: a study into lived experiences of participants in Dutch arts-based recovery initiatives. [PDF]

Front Public Health
Boumans J, Oderwald A, Kroon H.
europepmc   +1 more source

Fine and gray competing risk regression model of predictors of loss to follow up among female sex workers receiving antiretroviral therapy in Nigeria: 2016-2022. [PDF]

BMC Womens Health
Ng'ambi WF, Kalaiwo A, Estill J, Orel E, Adoration C, Nwosu KD, Keiser O.   +6 more
europepmc   +1 more source

The impact of dolutegravir on the growth of HIV-exposed uninfected infants: an observational cohort study in rural Tanzania. [PDF]

EClinicalMedicine
Glanzmann S, Luoga E, Okuma J, Dotto E, Sigalla G, Franzeck FC, Nyenza E, Mnzava D, Bukuku M, Moshi L, Wilson L, Paris DH, Glass TR, Mollel GJ, Weisser M, Vanobberghen F, KIULARCO Study Group.   +16 more
europepmc   +1 more source